Drug intelligence / Profile preview

DS06652923

Development stage: Unknown
Lead developer: Daiichi Sankyo

Overview

DS06652923: sourced facts only. name: "Herein, we describe the discovery of DS06652923, a novel, potent, and orally available EGFR-triple-mutant inhibitor." [PMID:39111073]; target: "Herein, we describe the discovery of DS06652923, a novel, potent, and orally available EGFR-triple-mutant inhibitor." [PMID:39111073]; developer: "Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: [email protected]." [PMID:39111073]; stage: "The most optimized compound, DS06652923, achieved tumor regression in the Ba/F3 allograft model upon its oral administration." [PMID:39111073]

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on DS06652923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS06652923.